To evaluate whether intravenously administered nimodipine for a period of 5 days, followed by oral nimodipine until day 21, improves neurological and functional outcome in acute ischemic stroke patients.
- Nimodipine (Nimotop®)Drug
Other Names: The treatment group Intervention Desc: Calcium channel blocker (L-type calcium channels)
Randomized, double-blind, placebo-controlled trial of 295 patients at 34 centers.
Patients were randomized to receive 1 or 2 mg/h intravenous nimodipine or placebo for 5 days. This was followed by 16 days of treatment with oral nimodipine (30 mg four times daily) or placebo. Patients were assessed at baseline and on days 1, 2, 3, 5, 7, and 21 of treatment as well as weeks 12 and 24 after entry.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Neurological status as assessed by the Orgogozo scale and functional status as assessed by Barthel Index at day 21.|
|Secondary||Orgogozo, Mathew scale and Barthel Index scores at weeks 12 and 24.|